Published December 8, 2023 | Version v1
Journal article Open

Interleukin-6: Unravelling its role in sarcopenia pathogenesis and exploring therapeutic avenues

Authors/Creators

  • 1. Medical University - Sofia, Sofia, Bulgaria
  • 2. Department of Endocrinology - Medical Institute of the Ministry of Interior, Sofia, Bulgaria
  • 3. University Hospital Medica Cor, Ruse, Bulgaria
  • 4. Sofia University St. Kliment Ohridski, Sofia, Bulgaria

Description

This review explores the intricate relationship between interleukin-6 (IL-6) and sarcopenia, a prevalent condition characterized by progressive skeletal muscle loss, particularly in aging populations. Emphasizing the rising prevalence and health challenges posed by sarcopenia, the paper delves into the multifunctional roles of IL-6 in immune response, inflammation and inflammaging associated with sarcopenia. Significantly elevated in sarcopenic individuals, IL-6 prompts an exploration of its molecular impact on muscle wasting. The review critically assesses IL-6 as a potential biomarker for sarcopenia diagnosis and prognosis while also examining therapeutic interventions targeting IL-6 signaling pathways, offering a foundation for future research and the development of targeted therapeutic strategies to alleviate the impact of this debilitating condition.

Files

PHAR_article_115762.pdf

Files (457.7 kB)

Name Size Download all
md5:3af3a3a9818c988be95b554e8ac84b21
380.7 kB Preview Download
md5:3c4958d37b73fe39446efcd2178134f4
77.1 kB Preview Download

Additional details

Cites
Publication: 10.1113/JP281220 (DOI)
Publication: 10.3390/ijms232315039 (DOI)
Publication: 10.3390/ijms241713181 (DOI)
Publication: 10.1186/2046-2395-2-8 (DOI)
Publication: 10.1093/gerona/glaa154 (DOI)
Publication: 10.1136/annrheumdis-2022-eular.1221 (DOI)
Publication: 10.1152/ajpendo.00039.2012 (DOI)
Publication: 10.1093/gerona/glp196 (DOI)
Publication: 10.3390/cancers15092406 (DOI)
Publication: 10.1038/nm.3720 (DOI)
Publication: 10.1111/j.1749-6632.2000.tb06651.x (DOI)
Publication: 10.1046/j.1532-5415.2002.50605.x (DOI)
Publication: 10.1152/ajpendo.1991.260.5.E727 (DOI)
Publication: 10.1152/japplphysiol.01026.2004 (DOI)
Publication: 10.1186/s13075-022-02858-y (DOI)
Publication: 10.21037/atm-20-7269 (DOI)
Publication: 10.1002/jcsm.12762 (DOI)
Publication: 10.2174/1389203718666170607113459 (DOI)
Publication: 10.1111/jgs.12840 (DOI)
Publication: 10.1016/j.exger.2022.111931 (DOI)
Publication: 10.56543/aaeeu.2023.2.1.05 (DOI)
Publication: 10.3390/ijms21176290 (DOI)
Publication: 10.1016/S0047-6374(03)00027-7 (DOI)
Publication: 10.1186/s12877-018-1007-9 (DOI)
Publication: 10.1016/j.amjmed.2005.10.049 (DOI)
Publication: 10.1093/gerona/glp097 (DOI)
Publication: 10.1093/gerona/55.12.M709 (DOI)
Publication: 10.1152/physiolgenomics.00151.2009 (DOI)
Publication: 10.1093/mr/roac095 (DOI)
Publication: 10.1152/ajpendo.00353.2004 (DOI)
Publication: 10.1159/000505099 (DOI)
Publication: 10.3748/wjg.v26.i16.1912 (DOI)
Publication: 10.1093/gerona/57.5.M326 (DOI)
Publication: 10.1002/jcsm.13193 (DOI)
Publication: 10.1126/sciadv.abd9502 (DOI)
Has part
Figure: 10.3897/pharmacia.70.e115762.figure1 (DOI)

References

  • Addinsall AB, Cacciani N, Akkad H, Salah H, Tchkonia T, Kirkland JL, Larsson L (2021) JAK/STAT inhibition augments soleus muscle function in a rat model of critical illness myopathy via regulation of complement C3/3R. The Journal of Physiology 599(11): 2869–2886. https://doi.org/10.1113/JP281220
  • Antuña E, Cachán-Vega C, Bermejo-Millo JC, Potes Y, Caballero B, Vega-Naredo I, Coto-Montes A, Garcia-Gonzalez C (2022) Inflammaging: Implications in Sarcopenia. International Journal of Molecular Sciences 23(23): 15039. https://doi.org/10.3390/ijms232315039
  • Bermejo-Álvarez I, Pérez-Baos S, Gratal P, Medina JP, Largo R, Herrero-Beaumont G, Mediero A (2023) Effects of Tofacitinib on Muscle Remodeling in Experimental Rheumatoid Sarcopenia. International Journal of Molecular Sciences 24(17): 13181. https://doi.org/10.3390/ijms241713181
  • Baylis D, Bartlett DB, Patel HP, Roberts HC (2013) Understanding how we age: Insights into inflammaging. Longevity & Healthspan 2(1): 8. https://doi.org/10.1186/2046-2395-2-8
  • Bermejo-Bescós P, Martín-Aragón S, Cruz-Jentoft AJ, Merello de Miguel A, Vaquero-Pinto MN, Sánchez-Castellano C (2020) Peripheral IL-6 Levels but not Sarcopenia Are Predictive of 1-Year Mortality After Hip Fracture in Older Patients. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 75(10): e130–e137. https://doi.org/10.1093/gerona/glaa154
  • Bermejo I, Pérez-Baos S, Medina JP, Gratal P., Prieto-Potin I, Largo R (2022) Pharmacological inhibition of IL-6/JAK/STAT axis increases muscle mass in an experimental model of sarcopenia associated to rheumatoid arthritis. Annals of the Rheumatic Diseases 81(1): 1165. https://doi.org/10.1136/annrheumdis-2022-eular.1221
  • Bonetto A, Aydogdu T, Jin X, Zhang Z, Zhan R, Puzis L, Koniaris LG, Zimmers TA (2012) JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. American journal of physiology. Endocrinology and Metabolism 303(3): E410–E421. https://doi.org/10.1152/ajpendo.00039.2012
  • Buford TW, Cooke MB, Manini TM, Leeuwenburgh C, Willoughby DS (2010) Effects of age and sedentary lifestyle on skeletal muscle NF-kappa B signaling in men. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 65(5): 532–537. https://doi.org/10.1093/gerona/glp196
  • Dalbeni A, Natola LA, Garbin M, Zoncapè M, Cattazzo F, Mantovani A, Vella A, Canè S, Kassem J, Bevilacqua M, Conci S, Campagnaro T, Ruzzenente A, Auriemma A, Drudi A, Zanoni G, Guglielmi A, Milella M, Sacerdoti D (2023) Interleukin-6: A new marker of advanced-sarcopenic HCC cirrhotic patients. Cancers 15(9): 2406. https://doi.org/10.3390/cancers15092406
  • Doles JD, Olwin BB (2014) The impact of JAK-STAT signaling on muscle regeneration. Nature Medicine 20(10): 1094–1095. https://doi.org/10.1038/nm.3720
  • Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E, De Benedictis G (2000) Inflamm-aging. An evolutionary perspective on immunosenescence. New York Academy of Sciences 908(1): 244–254. https://doi.org/10.1111/j.1749-6632.2000.tb06651.x
  • Ferrucci L, Penninx B, Volpato S, Harris T, Bandeen-Roche K, Balfour J, Leveille S, Fried L, Guralnik J (2002) Change in muscle strength explains accelerated decline of physical function in older women with high interleukin-6 serum levels. Journal of the American Geriatrics Society 50(12): 1947–1954. https://doi.org/10.1046/j.1532-5415.2002.50605.x
  • Goodman MN (1991) Tumor necrosis factor induces skeletal muscle protein breakdown in rats. American Journal of Physics 260(5 Pt 1): 727–730. https://doi.org/10.1152/ajpendo.1991.260.5.E727
  • Haddad F, Zaldivar F, Cooper DM, Adams GR (1985) IL-6-induced skeletal muscle atrophy. Journal of Applied Physiology [2005] 98(3): 911–917. https://doi.org/10.1152/japplphysiol.01026.2004
  • Hein TR, Peterson L, Bartikoski BJ, Portes J, Esprito RC, Xavier S, Xavier RM (2022) The effect of disease-modifying anti-rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta-analysis. Arthritis Research & Therapy 24(1): 171. https://doi.org/10.1186/s13075-022-02858-y
  • Huang Z, Zhong L, Zhu J, Xu H, Ma W, Zhang L, Shen Y, Law BY, Ding F, Gu X, Sun H (2020) Inhibition of IL-6/JAK/STAT3 pathway rescues denervation-induced skeletal muscle atrophy. Annals of Translational Medicine 8(24): 1681. https://doi.org/10.21037/atm-20-7269
  • Lambert CP (2021) Anti-cachexia therapy should target metabolism, inflammatory cytokines, and androgens in hormone-independent cancers. Journal of Cachexia, Sarcopenia and Muscle 12(5): 1352–1353. https://doi.org/10.1002/jcsm.12762
  • Landi F, Calvani R, Cesari M, Tosato M, Martone AM, Ortolani E, Savera G, Salini S, Sisto A, Picca A, Marzetti E (2018) Sarcopenia: An overview on current definitions, diagnosis and treatment. Current Protein & Peptide Science 19(7): 633–638. https://doi.org/10.2174/1389203718666170607113459
  • Legrand D, Vaes B, Mathei C, Adriaensen W, Van Pottelbergh G, Degryse JM (2014) Muscle strength and physical performance as predictors of mortality, hospitalization, and disability in the oldest old. Journal of the American Geriatrics Society 62(6): 1030–1038. https://doi.org/10.1111/jgs.12840
  • Liang Z, Zhang T, Liu H, Li Z, Peng L, Wang C, Wang T (2022) Inflammaging: The ground for sarcopenia? Experimental Gerontology 168: 111931. https://doi.org/10.1016/j.exger.2022.111931
  • Miteva D, Velikova T (2023) Epigenetic alterations in gene expression in the aging immune system. Anti-Aging Eastern Europe 2(1): 29–35. https://doi.org/10.56543/aaeeu.2023.2.1.05
  • Patsalos O, Dalton B, Himmerich H (2020) Effects of IL-6 Signaling Pathway Inhibition on Weight and BMI: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences 21(17): 6290. https://doi.org/10.3390/ijms21176290
  • Pedersen M, Bruunsgaard H, Weis N, Hendel HW, Andreassen BU, Eldrup E, Dela F, Pedersen BK (2003) Circulating levels of TNF-alpha and IL-6-relation to truncal fat mass and muscle mass in healthy elderly individuals and in patients with type-2 diabetes. Mechanisms of Ageing and Development 124(4): 495–502. https://doi.org/10.1016/S0047-6374(03)00027-7
  • Rong YD, Bian AL, Hu HY, Ma Y, Zhou XZ (2018) Study on relationship between elderly sarcopenia and inflammatory cytokine IL-6, anti-inflammatory cytokine IL-10. BMC Geriatrics 18: 308. https://doi.org/10.1186/s12877-018-1007-9
  • Schaap LA, Pluijm SM, Deeg DJ, Visser M (2006) Inflammatory markers and loss of muscle mass (sarcopenia) and strength. The American Journal of Medicine 119(6): 526.e9–526.e17. https://doi.org/10.1016/j.amjmed.2005.10.049
  • Schaap LA, Pluijm SM, Deeg DJ, Harris TB, Kritchevsky SB, Newman AB, Colbert LH, Pahor M, Rubin SM, Tylavsky FA, Visser M (2009) Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. The Journals of Gerontology, Series A, Biological Sciences and Medical Sciences 64(11): 1183–1189. https://doi.org/10.1093/gerona/glp097
  • Taaffe DR, Harris TB, Ferrucci L, Rowe J, Seeman TE (2000) Cross-sectional and prospective relationships of interleukin-6 and C-reactive protein with physical. performance in elderly persons: MacArthur studies of successful aging. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 55(12): M709–M715. https://doi.org/10.1093/gerona/55.12.M709
  • Thalacker-Mercer AE, Dell'Italia LJ, Cui X, Cross JM, Bamman MM (2010) Differential genomic responses in old vs. young humans despite similar levels of modest muscle damage after resistance loading. Physiological Genomics 40(3): 141–149. https://doi.org/10.1152/physiolgenomics.00151.2009
  • Torii M, Itaya T, Minamino H, Katsushima M, Fujita Y, Tanaka H, Oshima Y, Watanabe R, Ito H, Arai H, Hashimoto M (2023) Management of sarcopenia in patients with rheumatoid arthritis. Modern Rheumatology 33(3): 435–440. https://doi.org/10.1093/mr/roac095
  • Toth MJ, Matthews DE, Tracy RP, Previs MJ (2005) Age-related differences in skeletal muscle protein synthesis: relation to markers of immune activation. American Journal of Physiology. Endocrinology and Metabolism 288(5): E883–E891. https://doi.org/10.1152/ajpendo.00353.2004
  • Uciechowski P, Dempke WCM (2020) Interleukin-6: A masterplayer in the cytokine network. Oncology 98(3): 131–137. https://doi.org/10.1159/000505099
  • Velikova T, Miteva L, Stanilov N, Spassova Z, Stanilova SA (2020) Interleukin-6 compared to the other Th17/Treg related cytokines in inflammatory bowel disease and colorectal cancer. World journal of gastroenterology 26(16): 1912–1925. https://doi.org/10.3748/wjg.v26.i16.1912
  • Visser M, Pahor M, Taaffe DR, Goodpaster BH, Simonsick EM, Newman AB, Nevitt M, Harris TB (2002) Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the health ABC study The Journals of Gerontology, Series A, Biological Sciences and Medical Sciences 57(5): M326–M332. https://doi.org/10.1093/gerona/57.5.M326
  • Xie T, Lv T, Zhang T, Feng D, Zhu F, Xu Y, Gu L, Guo Z, Ding C, Gong J (2023) Interleukin-6 promotes skeletal muscle catabolism by activating tryptophan– indoleamine 2,3-dioxygenase 1–kynurenine pathway during intra-abdominal sepsis. Journal of Cachexia, Sarcopenia and Muscle 14(2): 1046–1059. https://doi.org/10.1002/jcsm.13193
  • Zhaowei C, Li BJ, Zhan RZ, Rao LJ, Bursac N (2021) Exercise mimetics and JAK inhibition attenuate IFN-γ–induced wasting in engineered human skeletal muscle. Science Advances 7(4): 9502. https://doi.org/10.1126/sciadv.abd9502